At a superficial level, Parkinson disease (PD) and cancer seem to be like the 2 sides of a coin: uncontrolled cell growth in cancer contrasting with untimely cell death in PD. The underlying mechanisms could therefore be 2 opposite endpoints of those intracellular pathways that regulate the cell cycle, cell death, and cell survival. 1 Extrapolating this point, if there is a systemic difference in a person's tendency of cells to undergo programmed cell death, then an individual who has increased risk of PD would have a lower risk for cancer and vice versa.
This hypothesis is supported by the results of a systematic review and meta-analysis of clinical and epidemiologic studies in which the risk of PD and cancer showed an inverse relationship. 2 However, at least some of these studies have methodologic shortcomings, and a recent study that controlled for known confounding factors did not reveal a significantly lower prevalence of cancer in patients with PD, either prior to the clinical diagnosis of PD or after they had developed clinically manifest PD. 3 The one exception is melanoma, which is more common in PD both before and after the diagnosis of PD is made. This led to the hypothesis that there are common pathogenic pathways in PD and melanoma. 4 In contrast to the simple cell death hypothesis outlined above, this suggests that the factors that lead to risk of cell death of nigral neurons are common to, and have the same direction of effect as, those that lead to risk of proliferation of melanocytes. Reassuringly, the increased risk of melanoma is independent of dopaminergic therapy.
While the precise links between molecular mechanisms leading to both sporadic PD and melanoma remain to be elucidated, increasing evidence is now emerging about distinct PD gene defects that are linked to cancer risk. The G2019S mutation in the leucine-rich repeat kinase 2 gene (LRRK2
G2019S
) is the single most common autosomal dominantly inherited PD gene defect. The LRRK2 protein is a scaffolding-type protein kinase, and LRRK2 G2019S is thought to lead to the disease by increasing the LRRK2 kinase activity resulting in increased phosphorylation of as yet mostly hypothetical targets, although whether all mutations in LRRK2 have the same biochemical mechanism is uncertain. 5 In this issue of Neurology ® , Inzelberg and coworkers 6 now report an increased incidence of non-skin cancer, but not for skin cancer, in patients with LRRK2 G2019S mutation with an age-adjusted odds ratio (OR) of 3.38. The data were particularly striking for breast cancer, but additional analysis excluding all breast cancer cases still revealed a significant increase of non-skin cancer cases among LRRK2 G2019S carriers. The results of this study are in keeping with a previous, smaller study. 7 Increased incidence of colon cancer has also been reported in mutation carriers belonging to the large "family D" with a different LRRK2 mutation (LRRK2 R144C ). 8 The study of Inzelberg and coworkers has several strengths, in particular the inclusion of a comparatively large number of patients with PD with (n ϭ 79) or without (n ϭ 411) the LRRK2 G2019S mutation. Mutation carriers and noncarriers were well matched for age and PD disease duration. However, there are also some important limitations. The specific LRRK2 G2019S mutation is particularly common in people of Ashkenazi heritage, but is found worldwide. The increased risk of non-skin cancer was only observed in Ashkenazi patients with PD with the LRRK2 G2019S mutation but not in LRRK2 G2019S -positive patients with PD with different ethnic background. However, the study was underpowered for the non-Ashkenazi LRRK2 G2019S patients with PD (n ϭ 9), and additional studies are needed to clarify this issue. Most importantly, this study does not prove causation, but reports an association. Because the LRRK2
shows incomplete penetrance even to old age, other factors must therefore determine whether LRRK2 G2019S mutation carriers develop PD or not. Such factors may include additional genetic factors, environmental factors in the broadest terms as well as stochastic events. Following this reasoning, it is possible that these additional factors result in the observed increased risk of cancer rather than the LRRK2 G2019S mutation itself. Also, there may be other shared factors increasing the risk for both PD and cancer in LRRK2 G2019S mutation carriers which are only present in the Ashkenazi population, which is why it is important to clarify whether the association holds across different human populations.
Equally, it could be the LRRK2 G2019S mutation itself that predisposes to cancer. LRRK2 belongs to the Roco protein family, members of which contain a RAS-like GTPase (or ROC) domain and a characteristic COR (C-terminal of ROC) domain. Intriguingly, 2 other human Roco proteins, DAPK1 and MFHAS1, have been implicated in the pathogenesis of cancer. For example, reduced expression of DAPK1 contributes to heritable predisposition to chronic lymphatic leukemia. 9 More directly supporting a role of LRRK2 in cancer, chromosomal amplification of the LRRK2 locus is required for oncogenic signaling in papillary renal and thyroid carcinomas. 10 A bioinformatics study investigating nonrandom clustering of somatic mutations in cancer tissue identified the kinase domain of LRRK2 as a possible mutation hot spot. 11 Given that LRRK2 is probably involved in general aspects of cellular signaling, is widely expressed throughout many cells, and that aberrant signaling contributes to oncogenesis, it is therefore reasonable to hypothesize that LRRK2 G2019S disrupts signaling, leading to proliferation of some cell populations.
Again, however, none of the available literature proves a causative relationship between LRRK2
and cancer. Clues may come from examining non-skin cancer rates in other populations with LRRK2 G2019S mutations, which has arisen at least 3 times independently in human history, and possibly other LRRK2 mutations. It is critical to then identify cellular mechanisms by which LRRK2 G2019S could lead to cancer.
Most importantly, both scientists and clinicians will have a duty to communicate these complicated findings to patients with PD and their relatives in a manner that is both sensible and sensitive. 
